Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 15/20 | 0.81 |
| ▸ | MAOA | P21397 | 2/20 | 0.66 |
| ▸ | ACHE | P22303 | 2/20 | 0.66 |
| ▸ | HASPIN | Q8TF76 | 4/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070349 | 0.89 | DYRK1A (1.00) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL23150325 | 0.88 | DYRK1A (0.73) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL13494641 | 0.87 | DYRK1A (0.66) | DYRK1AHTR2AHTR2C | |
| SCHEMBL2217478 | 0.86 | DYRK1A (0.74) | DYRK1AHASPINHTR2AHTR2C | |
| SCHEMBL20135938 | 0.86 | DYRK1A (0.66) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL23150312 | 0.85 | HASPIN (0.73) | DYRK1AHASPINHTR2AHTR2C | |
| SCHEMBL20340616 | 0.85 | DYRK1A (0.88) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL13874987 | 0.85 | DYRK1A (0.82) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL668477 | 0.84 | DYRK1A (1.00) | DYRK1AMAOAACHEHASPINHTR2A | |
| SCHEMBL12070353 | 0.83 | DYRK1A (0.73) | DYRK1AMAOAACHEHASPINHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-04-25 | — | — | US | disclosed |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-01-09 | — | — | US | disclosed |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2021-04-01 | — | — | US | disclosed |
| CN-112135613-A | Kinase inhibitor compounds and compositions and methods of use | 西奈山伊坎医学院 | 2020-12-25 | — | — | CN | disclosed |
| US-8772311-B2 | Harmine derivatives, intermediates used in their preparations, preparation processes and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| EP-1634881-B1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | XINJIANG HUASHIDAN PHARMACEUTICAL RES CO LTD (CN) | 2011-07-27 | — | — | EP | disclosed |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2009-09-10 | — | — | US | disclosed |
| EP-1634881-A1 | HARMINE DERIVATIVES, INTERMEDIATES USED IN THEIR PREPARATION, PREPARATION PROCESSES AND USE THEREOF | Xinjiang Huashidan Pharmaceutical Research Co., Ltd. (CN) | 2006-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132494-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, DYRK1A, CSNK1G3 | DYRK1A 2/4885MAOA 1013/4885ACHE 745/4885 |
| US-11866427-B2 | Kinase inhibitor compounds and compositions and methods of use | CSNK1A1, CSNK1E, CSNK1G3 | DYRK1A 7/4885MAOA 1312/4885ACHE 831/4885 |
| US-20090227619-A1 | Harmine derivatives, intermediates used in their preparations, preparation processes and use therefo | TPH1, HTR1F, TPH2 | DYRK1A 2398/4885MAOA 48/4885ACHE 208/4885 |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, CSNK1E, CSNK1G3 | DYRK1A 7/4885MAOA 1312/4885ACHE 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.